BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
Mar 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
5/8 — Partial
Priority Review
SOMAVERT (pegvisomant) by Pfizer. Approved for acromegaly. First approved in 2003.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMAVERT (pegvisomant) is a subcutaneous injectable biopharmaceutical product approved by the FDA on March 25, 2003, for the treatment of acromegaly. As a pegylated growth hormone receptor antagonist, it works by blocking growth hormone signaling at the receptor level, offering an alternative mechanism to somatostatin analogs. The product represents a specialized endocrinology treatment for patients with acromegaly who are inadequately controlled by or intolerant of other therapies.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (14)
Korean Regulatory Post Marketing Surveillance for Somavert
Started Jul 2022
100 enrolled
Acromegaly
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Started Oct 2019
12 enrolled
Pituitary Disease
Pasireotide LAR and Pegvisomant Study in Acromegaly
Started Aug 2015
60 enrolled
Acromegaly
A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects
Started Aug 2013
17 enrolled
Healthy Volunteers
Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
Started Mar 2011
10 enrolled
Adults Growth Hormone Deficiency.
Worked on SOMAVERT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.